Abingworth appoints Dr Andrew Sinclair public equities analyst
This article was originally published in Scrip
The life sciences and healthcare investment group Abingworth has appointed Dr Andrew Sinclairas principal, analyst. He will focus on evaluating new and existing opportunities in quoted life sciences and healthcare companies and will be based in the company's London headquarters. Dr Sinclair has more than eight years' experience as an analyst in the pharmaceutical and biotechnology sectors. He joined Abingworth from HSBC Global Markets, where he was senior equity analyst, director.